Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity

Swapnil M Parchand, Deepanshu Agrawal1, Anil Gangwe, Tripti Saraogi2, Deepshikha Agrawal

Purpose: To evaluate the efficacy of combined intravitreal ranibizumab (IVR) and zone I sparing laser ablation in infants with posterior zone I Retinopathy of Prematurity (ROP). Methods: This was a retrospective, interventional case series including premature infants diagnosed with posterior zone I ROP (n = 24) on ROP screening. Charts and RetCam images of preterm infants with posterior zone I ROP treated with immediate IVR and zone I sparing laser ablation at 4 weeks between April 2016 and September 2019 were reviewed. Data were analyzed and tabulated using frequency and descriptive statistics to describe the demographics, morphology, and treatment outcomes. Primary outcome measure was structural outcome at 6 months. It was further categorized as favorable and unfavorable. Results: Twenty-four infants (48 eyes) with a mean gestational age of 28.54 ± 1.98 weeks and birth weight of 1180.33 ± 280.65 grams were analyzed. Thirty-six (75%) eyes had persistent tunica vasculosa lentis and twenty-six (54.1%) eyes had iris neovascularization. All eyes had features of aggressive posterior retinopathy of prematurity (APROP) limited to posterior zone I. The mean duration between IVR and zone I sparing laser ablation was 29.62 ± 6.36 days (range: 24-34) days. One infant (2 eyes) received a second IVR treatment for recurrence of plus disease and persistent new vessels close to the fovea. Laser augmentation was done in 13 (27.1%) eyes. A favorable structural outcome was seen in 45 (93.7%) eyes. Conclusion: Posterior zone I ROP presents as APROP. Combined IVR and zone I sparing laser ablation appears effective treatment option in these eyes.

Key words: APROP, laser ablation, posterior zone I ROP, ranibizumab, retinopathy of prematurity, zone I ROP

Posterior zone I Retinopathy of Prematurity (ROP) is a subset of zone I ROP characterized by very posterior disease and poorly formed retinal vasculature.1-3 A literature search revealed only 3 studies reporting outcomes in posterior zone I ROP where unfavorable outcomes following laser treatment were seen in 78.6% to 100% eyes, while an intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents is an emerging treatment option for ROP.8,9 The RAINBOW trial reported a favorable outcome in 69% of eyes treated with intravitreal ranibizumab (IVR) as compared to 61% of eyes treated with laser treatment in zone I disease.10 Similarly, the BEAT-ROP study documented better outcomes with intravitreal bevacizumab (IVB) monotherapy compared with conventional laser therapy, in infants with zone I ROP.11 However, data on outcomes of anti-VEGF agents in posterior zone I disease is missing. Additionally, various studies reported reactivation of ROP ranging from 6.8% to 83% in eyes receiving anti-VEGF monotherapy for ROP.12,13 There are also concerns regarding optimal dosage, duration of recurrence, systemic safety, proper follow-up protocol and long-term functional outcomes following anti-VEGF monotherapy.

Several studies have now been advocating combined treatment to minimize the possible disadvantage of laser ablation and intravitreal anti-VEGF monotherapy.14-16 The rationale of a combined therapy is a possible synergistic effect of the blocking action of the existing vascular endothelial growth factor (VEGF) by anti-VEGF agents and suppression of further production of VEGF by laser ablation. This, a combined treatment might show a reduction in the reactivation rate and a need for repeat intravitreal anti-VEGF injection as well as achieving favorable structural outcome. Additionally, with zone I sparing peripheral laser ablation, a larger part of the central retina can be preserved. This treatment protocol may play a role in posterior zone I ROP which is the severest form of ROP. Hence, we investigated the structural outcome following combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I ROP.

Methods

A retrospective chart review was carried out for all infants diagnosed and treated for posterior zone I ROP at a tertiary eye care institute from April 2016 to September 2019. The Institutional Review Board approved the study and it adhered to the tenets of the declaration of Helsinki. All the premature infants, born at gestational age (GA) of less than 34 weeks or having birth weight (BW) less than 2000 grams, were screened for ROP. In this study, we included infants with posterior zone...
I ROP who were treated with IVR at presentation followed by zone I sparing laser ablation at 4 weeks and completed follow-up of at least 6 months. We excluded infants with incomplete records or those lost to follow-up. Aggressive posterior retinopathy of prematurity was defined in accordance with the revised International Classification of Retinopathy of Prematurity (ICROP) classification.[1-7] In addition to this, posterior zone I was defined as the area within a circle centered around the optic disc, the radius of which extends from the center of the optic disc to the center of the macula.[6,7] This area is approximately half of the area covered under zone I [Fig. 1].

At the initial screening, demographic details of the infants like name, gestational age (GA) at birth, gender, birth weight (BW) and post menstrual age (PMA) at the time of first screening were noted. Details of various risk factors like supplemental oxygen therapy, blood transfusion and post-natal infection/sepsis were gathered. Clinical characteristics like pupillary dilatation, neovascularization of the iris (NVI), tunica vasculosa lentis (TVL), clarity of the lens, vitreous haze, plus disease, optic disc, development of foveal vascularization and vessels in the periphery were studied. Retinopathy of Prematurity was documented using detailed retinal drawings on the clinical records. Our institute acquired RetCam (RetCam™ Shuttle; CLARITY, USA) in March 2019. Therefore, RetCam documentation was possible only for those babies presenting after this period.

After the diagnosis, treatment was initiated within 24 hours. Infants diagnosed with posterior zone I ROP received IVR in the operation theatre under anesthetic supervision once specially designed informed consent was signed by parents. Proparacaine hydrochloride (0.5%) eye drops was administered once 10 minutes before the injection. Lids were cleaned with 10% povidone-iodine and 5% povidone-iodine was instilled 5 minutes before the procedure followed by draping of eyes. A scrubbed operating theatre nurse held the infant’s head during the procedure. The injection was administered with a 30 gauge needle 1 mm away from the limbus. All infants received 0.25 mg/0.025 ml of ranibizumab intravitreally. Topically 0.3% tobramycin eye drops were administered 4 times daily for a week. Following this injection, the infants were followed up on Day 1, Day 7 and subsequently on a weekly basis till 4 weeks. On every follow-up visit, changes in the clinical findings were noted along with signs of regression, pattern of retinal vascularization, the development of staged ROP, if any, or progression. At approximately 4 weeks follow-up, infants were scheduled to undergo zone I sparing confluent laser ablation, as the second modality of treatment. Before laser ablation was performed, the infant’s eyes were dilated using 0.4% tropicamide and 2.5% phenylephrine eye drops. Laser ablation was done under topical anesthesia using 810 nm diode laser (IRIDEX®, GERMANY) in the presence of a neonatologist at the neonatal intensive care unit (NICU) with monitoring of vital parameters. Confluent laser burns were applied on the entire avascular retina 360° beyond zone I extending up to the ora serrata. Care was taken to delineate the area of zone I and the ill-defined posterior pole with lasers spots and then proceed. Laser spots were also applied inside the vascular loops outside zone I. All the laser treatments were completed in a single sitting. Following laser ablation, infants were again followed up on a fortnightly basis for 2 months and thereafter, once every month for the next 6 months. On the follow-up visits, apart from earlier mentioned clinical parameters, special attention was paid to detect recurrence of plus disease, development of any new vessels or fibrovascular proliferation. Laser augmentation was done if signs of recurrence of disease or any skip areas was noted. Recurrence was defined as reappearance of plus disease, progression of retinal neovascularization, new pre-retinal hemorrhage or membrane formation extending into the vitreous humor from retina.[10] Treatment details including number of laser spots, number of laser sessions and complications during the follow-up period were noted. The need for the 2nd injection of IVR despite the use of laser in progressive ROP was also noted.

The structural outcome at 6 months was categorized as favorable and unfavorable. A favorable structural outcome was defined as the absence of retinal arterial and venous tortuosity and engorgement, absence of fibrovascular traction and growth of vessels towards the avascular peripheral retina. An unfavorable structural outcome was defined as progression to tractional retinal detachment (TRD) or regression with cicatricial sequelae like development of falciform retinal fold or shortening of the major arcade vessels or temporal draging of fovea.

Statistical analysis

Data was transferred to a Microsoft Excel® spreadsheet and statistical analysis was carried out with SPSS version 16.0 (SPSS Inc, Chicago, IL). Quantitative and qualitative variables were expressed as mean ± standard deviation and percentages, respectively.

Results

This study comprised of 24 infants (48 eyes) who satisfied the inclusion criteria. [Table 1] The mean GA at birth was 28.54 ± 1.98 (range: 25-32) weeks and the mean BW was 1180.33 ± 280.65 (range: 785-2003) grams. There were 15 (62.5%) male infants. The mean PMA at the time of first ROP screening was 31.98 ± 2.03 (range: 29-36) weeks and the mean difference between GA at birth and PMA at first screening was 3.33 ± 1.0 (range: 2-7) weeks. The postnatal age of infants at first screening was 24.67 ± 8.57 (range: 14-52) days. Additional risk factors identified were supplemental oxygen therapy in 24 (100%) infants, postnatal sepsis in 6 (28.6%) infants, and blood transfusion in 4 (21%) infants.

On clinical examination, TVL was seen in 36 (75%) eyes, NVI in 26 (54.1%) eyes and poor pupillary dilatation in 24 (50%) eyes. Fovea was avascular in all eyes. All eyes had features suggestive of APROP including flat neovascularization and multiple vascular loops with intra-retinal shunts. Thirty six (75%) eyes had severe vascular dilation and tortuosity (plus disease) [Fig. 2a] whereas 12 (25%) eyes had deceptively thin caliber vessels over posterior pole ending in narrow vascular loops without any dichotomous branching [Fig. 2b].

All the infants received combined treatment. Intravitreal ranibizumab was administered within 24 hours of diagnosis. The mean duration between IVR and zone I sparing laser ablation was 29.62 ± 6.36 (range: 24-34) days. The mean number of laser spots per eye was 2856.5 ± 797.87. In 13 (27.1%) eyes, the ridge with retinal neovascularization developed temporal to the fovea at a mean of 3.15 ± 0.68 (range: 2 to 4) weeks following zone I sparing laser ablation. Therefore, laser augmentation was performed in these infants. The mean additional laser spots per eye was 482.54 ± 448.67. Overall, the mean number of laser sessions were 1.27. One infant (2 eyes) had recurrence of plus disease along with persistent flat neovascularization very close to the fovea in spite of laser augmentation. He received a second IVR injection in both the eyes following which plus disease and neovascularization regressed completely.

A favorable structural outcome at 6 months was noted in 45 (93.7%) eyes. [Fig. 3] An unfavorable structural outcome...
was noted in 3 (6.3%) eyes. Infant number 8 [Table 1], (BW: 785 grams, GA: 26 weeks) had stormy postnatal period with recurrent pneumonia and candida sepsis. He was on ventilatory support for 4 months. He received IVR and zone 1 sparing laser ablation (right eye [OD]: 2629 spots and left eye [OS]: 3057 spots) while being on ventilatory support. At 1 week follow up post laser therapy, hyphema was noted in OD. He was prescribed topical prednisolone acetate 1% eye drops 4 times a day and homatropine 1% eye drops 2 times a day for 2 weeks. At 3 weeks follow up post laser, hyphema resolved but 360 degree posterior synechiae and total cataract was noted in OD. At this visit infant was still on ventilatory support and continued to be in NICU setup for next 4 weeks. Infant was discharged at 8 weeks post laser therapy and referred to our base hospital for further ocular management. Ocular ultrasonography of OD revealed tractional retinal detachment. Despite undergoing pars plana lensectomy and vitrectomy at higher center, the eye developed phthisis bulbi. The left eye of the same infant showed a favorable structural outcome, with complete regression of ROP.

Infant number 16 (BW: 1050 grams, GA: 29 weeks) had multiple risk factors including supplementary oxygen, anemia (Hb: 8 gram%) and repeated blood transfusions. At first ROP screening both eyes (OU) had non-dilating pupils and NVI. She received IVR and zone 1 sparing laser ablation (OD: 4265 and OS: 4204 spots). During zone 1 sparing laser ablation, wedge shaped avascular area temporal to fovea within zone I was left unlasered. At 3 weeks follow up following primary laser, wedge shaped avascular area persisted with development of flat neovascularization in OU. Option of second IVR was given to parents but they did not consented. Hence, laser augmentation (OD: 320 and OS 280) was done. At 2 weeks post laser augmentation, neovascularization persisted in OD whereas it started regressing in OS. No skip areas were noted at this visit. At 4 weeks post laser augmentation, OD progressed to Stage 4 B. The patient was counselled for lens sparing vitrectomy but the parents refused any further surgical intervention. The left eye of the same infant showed a favorable structural outcome, with complete regression of neovascularization following laser augmentation.

Infant number 17 (BW: 900 grams, GA: 29 weeks) had delayed presentation at first ROP screening (PMA: 36 weeks). He also had non-dilating pupils and florid NVI. Additionally, OD had pre-retinal bleed at presentation. He received IVR and zone 1 sparing laser ablation (OD: 4248 and OS: 3961 spots). At follow up 2 and 4 weeks post laser ablation, pre-retinal bleed in OD decreased but still persisted. At 6 weeks, pre-retinal fibrosis was noted temporal to macula. At follow up 10 week, post laser, stage 4A was noted in OD. [Fig. 4a] Child underwent lens sparing vitrectomy at higher center. Following surgery, he has been on regular follow up and had good structural outcome. The left eye of the same infant showed a favorable structural outcome, with complete regression of ROP. [Fig. 4b]
Discussion

Posterior zone I ROP is considered to be the severest type of ROP. Very few studies have analyzed treatment outcomes in posterior zone I ROP. Two of these studies reported unfavorable outcomes in 100% eyes while Katoch et al. documented poor outcomes in 78.6% of eyes with laser treatment. The present study reports the largest data of the posterior zone I ROP where we treated these eyes with intravitreal ranibizumab at presentation followed by zone I sparing laser ablation at 4 weeks. Despite the severest form of ROP, we achieved favorable structural outcomes using the combined modality of treatment in 93.7% of eyes.

Posterior zone I is not described in ICROP classification. Kychenthal et al. first defined posterior zone I as the area within a circle centered around the optic disc, the radius of which extends from the center of the optic disc to the center of the macula. As this area is approximately half of zone I, some studies have mentioned this as zone half ROP instead of posterior zone I ROP. For uniform documentation this needs to be classified when new revision of ICROP classification is undertaken.

Various difficulties encountered in recognition of posterior zone I ROP include hazy cornea in extremely premature infants, poorly dilating pupils due to TVL and NVI, a virtually non-existent capillary network, deceptively thin caliber vessels and absence of a classical ridge. This may cause confusion regarding diagnosis of plus disease leading to errors in treatment and ultimately poor outcomes. Since, most of these extremely premature infants are sick requiring ventilatory support or oxygen therapy, pediatricians are also anxious to conduct ROP screening in their initial weeks. In our study, the mean age of infants at the time of first screening was $3.33 \pm 1.0$ weeks. This is one week before the western guidelines for first ROP screening. Katoch et al. reported that 75% of eyes in their study had non-dilating pupils and NVI whereas we found NVI and poorly dilating pupils in 54.1% and 50% of eyes, respectively. This difference could be because we carried out early screening in our study. Therefore, in most of the eyes diagnosis was done before the start of fibrovascular proliferation and this may have played an important role in achieving favorable outcomes in our study.

Retinal vascularization in zone I develops by vasculogenesis whereas vessels in zones II and III develop by angiogenesis. Vasculogenesis is the initial process by which vascularization starts at the optic disc at around 14 weeks of gestation and completes by 21 weeks of gestation. Fovea remains avascular till 25 weeks of gestation and development starts from 26 weeks by angiogenesis. In the present study, mean PMA at the first screening was $31.98 \pm 2.03$ weeks. Despite high PMA, we observed absence of foveal vascularization in all infants and
Table 1: Patient characteristics of infants with posterior zone I ROP

| Infant number | Sex | GA (weeks) | BW (grams) | Post-natal age at first screening (Days) | PMA at first screening (Weeks) | Eye | TVL | NVI | Non-Dilating Pupil | Interval between IVR and laser (Days) | Time between Primary and supplemental laser ablation (Weeks) (if any) | Follow up period (months) | Outcome |
|---------------|-----|------------|------------|------------------------------------------|-------------------------------|-----|-----|-----|---------------------|--------------------------------------|-----------------------------------------------------------------|--------------------------|---------|
| 1             | F   | 27         | 1200       | 23                                       | 30                            | OD  | A   | P   | A                  | 29                                   | -                                | 18                       | 1       |
|               |     |            |            |                                          |                               | OS  | A   | P   | A                  | 6                                    | -                                | 1                       |         |
| 2             | M   | 26         | 830        | 21                                       | 29                            | OD  | P   | A   | P                  | 26                                   | 4                                | 14                       | 1       |
|               |     |            |            |                                          |                               | OS  | P   | A   | P                  | 4                                    | -                                | 1                       |         |
| 3             | F   | 27         | 1155       | 23                                       | 30                            | OD  | P   | A   | P                  | 30                                   | -                                | 12                       | 1       |
|               |     |            |            |                                          |                               | OS  | P   | A   | A                  | 3                                    | -                                | 1                       |         |
| 4             | F   | 30         | 1150       | 20                                       | 33                            | OD  | P   | P   | A                  | 32                                   | 3                                | 15                       | 1       |
|               |     |            |            |                                          |                               | OS  | P   | P   | A                  | 3                                    | -                                | 1                       |         |
| 5             | F   | 29         | 960        | 36                                       | 34                            | OD  | P   | P   | P                  | 29                                   | -                                | 14                       | 1       |
|               |     |            |            |                                          |                               | OS  | P   | P   | P                  | 3                                    | -                                | 1                       |         |
| 6             | M   | 27         | 1245       | 19                                       | 30                            | OD  | P   | P   | A                  | 26                                   | -                                | 13                       | 1       |
|               |     |            |            |                                          |                               | OS  | P   | P   | A                  | 3                                    | -                                | 1                       |         |
| 7             | F   | 32         | 1560       | 17                                       | 35                            | OD  | P   | A   | P                  | 30                                   | -                                | 11                       | 1       |
|               |     |            |            |                                          |                               | OS  | P   | A   | A                  | 3                                    | -                                | 1                       |         |
| 8             | M   | 26         | 785        | 39                                       | 31                            | OD  | P   | A   | A                  | 27                                   | -                                | 10                       | 2       |
|               |     |            |            |                                          |                               | OS  | P   | A   | A                  | 3                                    | -                                | 1                       |         |
| 9             | F   | 32         | 1770       | 20                                       | 35                            | OD  | P   | A   | A                  | 32                                   | -                                | 11                       | 1       |
|               |     |            |            |                                          |                               | OS  | P   | A   | A                  | 3                                    | -                                | 1                       |         |
| 10            | M   | 30         | 1300       | 22                                       | 33                            | OD  | P   | P   | P                  | 27                                   | 3                                | 10                       | 1       |
|               |     |            |            |                                          |                               | OS  | P   | P   | P                  | 3                                    | -                                | 1                       |         |
| 11            | F   | 30         | 1415       | 20                                       | 33                            | OD  | A   | A   | A                  | 31                                   | -                                | 10                       | 1       |
|               |     |            |            |                                          |                               | OS  | A   | A   | A                  | 3                                    | -                                | 1                       |         |
| 12            | M   | 30         | 1100       | 20                                       | 33                            | OD  | A   | A   | A                  | 29                                   | -                                | 11                       | 1       |
|               |     |            |            |                                          |                               | OS  | A   | A   | A                  | 3                                    | -                                | 1                       |         |
| 13            | M   | 30         | 1200       | 23                                       | 33                            | OD  | P   | P   | P                  | 34                                   | -                                | 15                       | 1       |
|               |     |            |            |                                          |                               | OS  | P   | P   | P                  | 3                                    | -                                | 1                       |         |
| 14            | M   | 32         | 2003       | 14                                       | 34                            | OD  | P   | P   | A                  | 31                                   | -                                | 12                       | 1       |
|               |     |            |            |                                          |                               | OS  | P   | P   | A                  | 3                                    | -                                | 1                       |         |
| 15            | M   | 25         | 900        | 35                                       | 29                            | OD  | P   | A   | P                  | 24                                   | 4                                | 9                       | 1       |
|               |     |            |            |                                          |                               | OS  | P   | A   | P                  | 4                                    | -                                | 1                       |         |
| 16            | F   | 29         | 1050       | 16                                       | 31                            | OD  | P   | P   | P                  | 33                                   | 3                                | 7                       | 2       |
|               |     |            |            |                                          |                               | OS  | P   | P   | P                  | 3                                    | -                                | 1                       |         |
| 17            | M   | 29         | 900        | 52                                       | 36                            | OD  | A   | P   | P                  | 30                                   | -                                | 6                       | 2       |
|               |     |            |            |                                          |                               | OS  | A   | P   | P                  | 3                                    | -                                | 1                       |         |
| 18            | M   | 28         | 875        | 23                                       | 31                            | OD  | P   | A   | A                  | 29                                   | 2                                | 6                       | 1       |
|               |     |            |            |                                          |                               | OS  | P   | A   | A                  | 2                                    | -                                | 1                       |         |
| 19            | M   | 28         | 1070       | 20                                       | 31                            | OD  | P   | A   | A                  | 33                                   | -                                | 6                       | 1       |
|               |     |            |            |                                          |                               | OS  | P   | A   | A                  | 3                                    | -                                | 1                       |         |
| 20            | M   | 26         | 1100       | 23                                       | 29                            | OD  | P   | P   | P                  | 31                                   | -                                | 6                       | 1       |
|               |     |            |            |                                          |                               | OS  | P   | P   | P                  | 3                                    | -                                | 1                       |         |
| 21            | M   | 27         | 1185       | 20                                       | 30                            | OD  | P   | P   | P                  | 31                                   | -                                | 6                       | 1       |
|               |     |            |            |                                          |                               | OS  | P   | P   | P                  | 3                                    | -                                | 1                       |         |
| 22            | M   | 29         | 1145       | 30                                       | 33                            | OD  | A   | P   | P                  | 29                                   | -                                | 6                       | 1       |
|               |     |            |            |                                          |                               | OS  | A   | P   | P                  | 3                                    | -                                | 1                       |         |
| 23            | M   | 28         | 1280       | 30                                       | 32                            | OD  | P   | P   | A                  | 29                                   | -                                | 6                       | 1       |
|               |     |            |            |                                          |                               | OS  | P   | P   | A                  | 3                                    | -                                | 1                       |         |

Contd...
retinal vascularization was restricted to posterior zone I at the
time of the first screening. Therefore, apart from a defect in
vasculogenesis, factors like unblended oxygen administration
may account for severe capillary dropout in zone I disease. Shah
et al. reported oxygen exposure led to a loss of the vascularized
retina as well as retraction of capillary networks from zone II to
zone I or zone I anterior to zone II posterior.\[23] Since all infants
in this cohort were from level II NICUs, it is possible that they
might have received prolonged unmonitored oxygen resulting
in severe vaso-oblitervation.

Studies have shown that zone I disease is less responsive to
laser therapy as compared to zone II.\[10‑12,21] The Early Treatment
for Retinopathy of Prematurity study reported unfavorable
outcomes in 55.2% of eyes with zone I ROP compared to laser monotherapy.\[5] Previous studies reported 78.6% to 100% unfavorable outcomes in eyes with posterior zone I ROP treated with laser alone.\[26,27] Possible explanations for poor outcomes in zone I disease with laser therapy are a) laser treatment leads to destruction of neurons and source of VEGF 165 thus taking away hypoxic stimulus for VEGF production, b) zone I ROP may be driven by molecular signals other than VEGF or c) source of VEGF like vitreal macrophages are responsible for lack of effectiveness of laser therapy in zone I disease.\[23]

Recently, a few studies have reported the role of anti-VEGF agents in treatment of zone I ROP.\[28,29] Shah et al. in their series of zone I APROP reported growth of capillary networks up to zone II as well as opening up of thrombosed vessels on fluorescein angiogram in eyes treated with intravitreal bevacizumab (IVB).\[29] Padhi et al. reported three phases of vascular changes following IVB in eyes with zone I ROP mainly phase 1: rapid regression of plus disease; phase 2: slow vascular development and lastly, phase 3: there may be complete regression on follow-up or progression to rebound/ recurrent ROP.\[23]

Various studies have reported a recurrence of ROP following
intravitreal anti-VEGF injection ranging from 6.8% to 83%.\[10‑13] In
a large series of 626 eyes of 331 premature infants with ROP
treated with IVR, the rate of recurrence with type I prethreshold
ROP was 15.9%, 38.2% with threshold ROP and 66.7% with
APROP.\[21] The recurrence rate was significantly higher in
zone I (61.6%) ROP than zone II ROP (31%). Also, the mean
time to recurrence was 8.57 ± 3.73 weeks and it occurred as
early as 4 weeks. Wong et al. observed 83% of eyes treated with
IVR for zone I or posterior zone II diseases had reactivation
of ROP after the initial response to treatment with a mean
treatment to reactivation interval of 5.9 weeks.\[13] Although
various studies have shown a better systemic safety profile of
ranibizumab over bevacizumab, the possibility of reactivation
of ROP is higher and earlier with ranibizumab.\[34‑36] According
to Rainbow trial, the elimination rate of ranibizumab from
the eye was faster in infants when compared to adults (t1/2:
5.6 [infants] vs 8.6 days [adults]).\[38,39] This could be due to several
factors that includes structural difference in tissues, shorter
vitreous diffusion pathway within smaller eye and reduced
blood-retina vessel barrier function in active ROP. Kim et al.
reported excellent anatomical outcomes with combined IVB
and zone I sparing laser photoocoagulation in zone I ROP.\[30]
All eyes showed prompt regression of neovascular pathology
and plus disease without recurrence in their series. Katoch et al.
studied treatment outcome in posterior zone I ROP where 5 of
6 (83.3%) eyes receiving combined treatment with IVB followed
by laser photoocoagulation had favorable outcome while only 7
of 50 (14%) eyes treated with laser monotherapy had favorable
outcome.\[40] From above evidences combined treatment looks
promising approach while managing these eyes with posterior
zone I ROP but the guidelines regarding timing of laser therapy
following IVR are not available. Hence, considering posterior
zone I ROP as severest form of ROP with very high and early
recurrences as well as from above evidences, we decided to
planned zone I sparing laser treatment at 4 weeks following
IVR in all infants with posterior zone I ROP.

Combined IVR with zone I sparing laser photoocoagulation
in posterior zone I ROP have many advantages.\[14‑16] It reduces
the number of injections needed since only a minimal section
of the retina is vascularized in posterior zone I ROP. Hence, if
anti-VEGF monotherapy is planned, more than 2 anti-VEGF
injections might be required till the retina is completely
vascularized.\[22] Secondly, the persistent area of peripheral
avascular retina can lead to late exudative and tractional
consequences which can be prevented by performing early
laser. Infants receiving IVR monotherapy require close follow
ups to identify recurrences and might even require examination
under anesthesia after a certain age. This is especially important
in developing countries like India where follow up is big
challenge and dropout rate is high. Missing recurrence in
between follow up visit could lead to development of rapid
retinal detachment in posterior zone I disease.

The limitations of our study are that it is a retrospective
study from a single institution with limited follow-up. As we
performed laser ablation on all patients following IVR at 4 weeks,
we could not include a control group of IVR monotherapy or
another group where laser ablation could have been delayed till
time of recurrence after IVR. It would be interesting to see the
pattern of recurrence in these eyes with posterior zone I ROP.
Secondly, fundus fluorescein angiography was not performed
in these eyes. Hence, nature of foveal vascularization can only
be presumed. Lastly, refractive outcomes of the patients are not
mentioned. Nevertheless, the present study has many strengths
that include the largest cohort of infants with posterior zone I
ROP receiving uniform treatment protocol. Importantly, in eyes
where reported favorable outcomes in previous studies ranged
from 0 to 21.4%, we could document favorable outcomes of 93.7%
with IVR and zone I sparing laser ablation.

---

**Table 1: Contd...**

| Infant number | Sex | GA (weeks) | BW (grams) | Post-natal age at first screening (Days) | PMA at first screening (Weeks) | Eye | TVL | NVI | Non-Dilating Pupil | Interval between IVR and laser (Days) | Time between Primary and supplemental laser ablation (Weeks) (if any) | Follow up period (months) | Outcome |
|---------------|-----|------------|------------|----------------------------------------|-----------------------------|-----|-----|-----|-------------------|--------------------------------|-------------------------------------|-----------------------------|---------|
| 24            | F   | 28         | 1150       | 26                                      | 32                          | OD  | A   | A   | A                 | 29                              | -                                    | 6              | 1       |
| 25            | M   | 29         | 1200       | 27                                      | 35                          | OS  | A   | A   | A                 | 30                              | -                                    | 6              | 1       |

F: Female, M: Male, GA: Gestational Age, BW: Birth Weight, PMA: Post Menstrual Age, TVL: Tunica Vasculosa Lentis, NVI: Neovascularization of Iris, A: Absent, P: Present, IVR: Intravitreal Ranibizumab, Outcome: 1- Favorable outcome, 2- Unfavorable outcome
Conclusion

In conclusion, posterior zone I ROP presents as APROP and high index of suspicion is a must for early diagnosis. Combined treatment with IVR and zone I sparing laser ablation appears an effective treatment approach in eyes with posterior zone I ROP.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 2005;123:991-9.

2. Sanghi G, Dogra MR, Das P, Vinekar A, Gupta A, Dutta S. Aggressive posterior retinopathy of prematurity in Asian Indian babies: Spectrum of disease and outcome after laser treatment. Retina 2009;29:1335-9.

3. Sanghi G, Dogra MR, Katoch D, Gupta A. Aggressive posterior retinopathy of prematurity: Risk factors for retinal detachment despite confluent laser photocoagulation. Am J Ophthalmol 2013;155:159-64.

4. Cryotherapy for retinopathy of prematurity cooperative group. Multicenter trial of cryotherapy for retinopathy of prematurity: Three-month outcome. Arch Ophthalmol 1990;108:195-204.

5. Early treatment for retinopathy of prematurity cooperative group. Revised indications for the treatment of retinopathy of prematurity: Results of early treatment for ROP randomized trial. Arch Ophthalmol 2003;121:1684-96.

6. Katoch D, Dogra MR, Aggarwal K, Sanghi G, Samanta R, Handa S, et al. Posterior zone I retinopathy of prematurity: Spectrum of disease and outcome after laser treatment. Can J Ophthalmol 2019;54:87-93.

7. Kychenthal A, Dorta P, Katz X. Zone I retinopathy of prematurity: Clinical characteristics and treatment outcomes. Retina 2006;26:511-5.

8. Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial. Lancet 2019;394:1551-9.

9. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+retinopathy of prematurity. N Engl J Med 2011;364:603-15.

10. Tandon M, Vishal MY, Kohli P, Rajan RP, Ramasamy K. Supplemental laser for eyes treated with bevacizumab monotherapy in severe retinopathy of prematurity. Ophthalmol Retina 2018;2:623-8.

11. Gunay M, Celik G, Gunay BO, Aktaş A, Karatekin G, Ovail F. Evaluation of 2-year outcomes following intravitreal bevacizumab injection (IVB) for aggressive posterior retinopathy of prematurity. Arq Bras Oftalmol 2015;78:300-4.

12. Feng J, Qian J, Jiang Y, Zhao M, Liang J, Yin H, et al. Efficacy of primary intravitreal Ranibizumab for retinopathy of prematurity in china. Ophthalmology 2017;124:408-9.

13. Wong R, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina 2015;35:675-80.

14. Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007;245:1727-30.

15. Lee JY, Chae JB, Yang SJ, Yoon YH, Kim JG. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol 2010;248:1257-62.

16. Kim J, Kim S, Chang Y, Park W. Combined intravitreal Bevacizumab injection and Zone I sparing laser photocoagulation in patients with Zone I retinopathy of prematurity. Retina 2014;34:77-82.

17. Sanghi G, Dogra MR, Dogra M, Katoch D, Gupta A. A Hybrid form of retinopathy of prematurity. Br J Ophthalmol 2012;96:519-22.

18. Section on Ophthalmology American Academy of Pediatrics; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2006;117:572-6. Erratum in: Pediatrics 2006;118:1324.

19. Wilkinson AR, Haines L, Head K, Fielder AR. UK retinopathy of prematurity guideline. Early Hum Dev 2008;84:71-4.

20. Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: Roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci 2000;41:1217-28.

21. Shah PK, Narendran V, Kalpana N. Aggressive posterior retinopathy of prematurity in large preterm babies in South India. Arch Dis Child Fetal Neonatal Ed 2012;97:F371-5.

22. Flynn JT, Chan-Ling T. Retinopathy of prematurity: Two distinct mechanisms that underlie zone 1 and zone 2 disease. Am J Ophthalmol 2006;142:46-59.

23. Padhi TR, Das T, Rath S, Pradhan L, Sutar S, Panda KG, et al. Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I. Eye (Lond) 2016;30:392-9.

24. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70.

25. Kong L, Bhatt AR, Demby AY, Coats DK, Li A, Rahman EZ, et al. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci 2015;56:956-61.

26. Been JV, Zoer B, Kloosterboer N, Kessels CG, Zimmermann LJ, van Iwaarden JF, et al. Pulmonary vascular endothelial growth factor expression and desaturated phospholipid content in a chicken model of hypoxia-induced fetal growth restriction. Neonatology 2010;97:183-9.

27. Simon M, Grone HJ, J ohren O, Kullmer J, Plate KH, Risau W, et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995;268:F240-50.

28. Wu WC, Lien R, Liao PJ, Wang NK, Chen YP, Chao AN, et al. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol 2015;133:391-7.

29. Vanden Broucke Y, Melia M, Yang MB, Hutchinson AK, Wilson LB, Lambert SR. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: A Report by the American Academy of Ophthalmology. Ophthalmology 2017;124:619-33.

30. Fidler M, Fleck B, Stahl A, Marlow N, Chastain J, Li J, et al. Ranibuzumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trial. Transl Vis Sci Technol 2020;9:43.

31. Xu L, Lu T, Tuomi L, Jumbe N, Lu J, Eppler S, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: A population approach. Invest Ophthalmol Vis Sci 2013;54:1616-24.

32. Yi Z, Su Y, Zhou Y, Zheng H, Ye M, Xu Y, et al. Effects of intravitreal ranibizumab in the treatment of retinopathy of prematurity in Chinese infants. Curr Eye Res 2016;41:1092-7.